Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dermatologic adverse events associated with targeted therapies for melanoma.

Expert opinion on drug safety - 1 Mar 2022

Scarpato Luigi, Festino Lucia, Vanella Vito, Madonna Gabriele, Mastroianni Massimo, Palla Marco, Ascierto Paolo Antonio

Abstract excerpt

INTRODUCTION: The development of new targeted therapies has considerably changed the therapeutic paradigm of melanoma, significantly increasing overall survival (OS) and progression-free survival (PFS). However, skin-related adverse sequelae might occur and impact on patients' quality of life. AREAS COVERED: In this article we will cover the most important dermatological toxicities related to BRAF and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Melanoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Targeted Therapy

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Quality of Life

Share to Skin Neoplasms

Source

Identifiers

PMID: 34595993
DOI: 10.1080/14740338.2022.1986000

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dermatologic adverse events associated with targeted therapies for melanoma.PMID 34595993Read ↗

Dermatological adverse events from BRAF inhibitors: a growing problem.Semantic proximity Read ↗

A comparative study of the cutaneous side effects between BRAF monotherapy and BRAF/MEK inhibitor combination therapy in patients with advanced melanoma: a single-centre experience.Semantic proximity Read ↗

Dermatological approach to vemurafenib skin toxicity: a single centre experience.Semantic proximity Read ↗

Cutaneous adverse events to type I BRAF inhibitors: an analysis of effects associated with each inhibitor and therapeutic time interval to onset.Semantic proximity Read ↗

Cutaneous melanoma.Semantic proximity Read ↗

Melanoma.Semantic proximity Read ↗

The melanoma revolution: from UV carcinogenesis to a new era in therapeutics.Semantic proximity Read ↗

Evolution of Molecular Targets in Melanoma Treatment.Semantic proximity Read ↗

[Management of toxicities of BRAF inhibitors and MEK inhibitors in advanced melanoma].Semantic proximity Read ↗

European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022.Semantic proximity Read ↗

Current Controversies and Challenges on BRAF V600K-Mutant Cutaneous MelanomaSemantic proximity Read ↗

Molecularly targeted therapies for melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.